ICU Medical reported second quarter 2025 revenue of $548.9 million, a decrease from $596.5 million in the prior year. Despite the revenue decline, the company achieved a GAAP net income of $35.3 million, a substantial improvement from a net loss in Q2 2024. Adjusted diluted EPS also saw a notable increase to $2.10.
Second quarter 2025 revenue was $548.9 million, a decrease from $596.5 million in the same period last year.
GAAP net income for Q2 2025 was $35.3 million, a significant turnaround from a GAAP net loss of $(21.4) million in Q2 2024.
Adjusted diluted earnings per share increased to $2.10 in Q2 2025, up from $1.56 in Q2 2024.
Adjusted EBITDA for the second quarter of 2025 was $100.3 million, an increase from $91.3 million in the prior year period.
For Fiscal Year 2025, ICU Medical updated its guidance, narrowing the range for GAAP net loss and adjusted EBITDA, while slightly increasing the lower end of the adjusted diluted earnings per share guidance.
Visualization of income flow from segment revenue to net income